Development and Validation of a Method for Determining Deferasirox in Human Blood Plasma by HPLC-UV-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Development and Validation of a Method for Determining Deferasirox in Human Blood Plasma by HPLC-UV

Published:2022-05-30 Issue:2 Volume:11 Page:187-196
ISSN:2658-5049
Container-title:Drug development & registration
language:
Short-container-title:Razrabotka i registraciâ lekarstvennyh sredstv

Author:

Karpova P. A.¹,Komarov T. N.²,Archakova O. A.²,Shchelgacheva D. S.²,Suvorova A. V.²,Bagaeva N. S.²,Karnakova P. K.¹,Shohin I. E.²

Affiliation:

1. LLC "CPHA"; I. M. Sechenov First MSMU of the Ministry of Health of the Russian Federation (Sechenov University)

2. LLC "CPHA"

Publisher

Center of Pharmaceutical Analytics Ltd

Subject

Drug Discovery,Pharmaceutical Science

Reference16 articles.

1. Díaz-García J. D., Gallegos-Villalobos A., Gonzalez-Espinoza L., Sanchez-Niño M. D., Villarrubia J., Ortiz A. Deferasirox Nephrotoxicity – the Knowns and Unknowns. Nature Reviews Nephrology. 2014;10(10):574–586. DOI: 10.1038/nrneph.2014.121.

2. Yang L. P. H., Keam S.J., Keating G. M. Deferasirox. A Review of its Use in the Management of Transfusional Chronic Iron Overload. Drugs. 2007;67(15): 2211–2230. DOI: 10.2165/00003495-200767150-00007.

3. Babaeva Т. N., Pospelova Т. I., Nechunaeva I. N. Formation of iron excess in patients with intermediateand lower-risk myelodysplastic syndrome. Siberian Scientific Medical Journal. 2019;39(1):77–83. (In Russ.) DOI: 10.15372/SSMJ20190111.

4. Bollig C., Schell L. K., Rücker G., Allert R., Motschall E., Niemeyer C. M., Bassler D., Meerpohl J. J. Deferasirox for Managing Iron Overload in People with Thalassaemia. Cochrane Database Systematic Reviews. 2017;8(8):CD007476. DOI: 10.1002/14651858.CD007476.pub3.

5. Timoshnikov V. A., Kichigina L. A., Selyutina O. Y., Polyakov N. E., Kontoghiorghes G. J. Antioxidant Activity of Deferasirox and its Metal Complexes in Model Systems of Oxidative Damage: Comparison with Deferiprone. Molecules. 2021;26(16):5064. DOI: 10.3390/molecules26165064.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Validation of a Liquid Chromatography-Tandem Mass Spectrometry Method for Analysis of Riluzole in Human Plasma and Its Application on a Bioequivalence Study;Drug development & registration;2023-02-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3